We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Medtronic (MDT - Free Report) ended the recent trading session at $82.90, demonstrating a +0.44% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.81%. Elsewhere, the Dow gained 1.56%, while the tech-heavy Nasdaq added 2.06%.
Shares of the medical device company have depreciated by 10.6% over the course of the past month, outperforming the Medical sector's loss of 12.01% and lagging the S&P 500's loss of 6.14%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on May 21, 2025. It is anticipated that the company will report an EPS of $1.58, marking an 8.22% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $8.81 billion, indicating a 2.57% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.46 per share and revenue of $33.48 billion, which would represent changes of +5% and +3.44%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Medtronic is currently a Zacks Rank #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 15.13. This indicates a premium in contrast to its industry's Forward P/E of 14.73.
One should further note that MDT currently holds a PEG ratio of 2.08. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.95.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 177, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Gains But Lags Market: What You Should Know
Medtronic (MDT - Free Report) ended the recent trading session at $82.90, demonstrating a +0.44% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.81%. Elsewhere, the Dow gained 1.56%, while the tech-heavy Nasdaq added 2.06%.
Shares of the medical device company have depreciated by 10.6% over the course of the past month, outperforming the Medical sector's loss of 12.01% and lagging the S&P 500's loss of 6.14%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on May 21, 2025. It is anticipated that the company will report an EPS of $1.58, marking an 8.22% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $8.81 billion, indicating a 2.57% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.46 per share and revenue of $33.48 billion, which would represent changes of +5% and +3.44%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Medtronic is currently a Zacks Rank #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 15.13. This indicates a premium in contrast to its industry's Forward P/E of 14.73.
One should further note that MDT currently holds a PEG ratio of 2.08. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.95.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 177, finds itself in the bottom 29% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.